The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Secondary CNS lymphoma: recent data and future approaches
Kate Cwynarski, MD, PhD, University College Hospital, London, UK, review recent data in secondary CNS lymphoma presented at ASH 2019, BSH 2020 and EHA 2020. Dr Cwynarski specifically discusses the IELSG 42 study evaluating the MARIETTA regimen in CNS lymphoma patients. Historically, CNS lymphoma has had poor outcomes, however, it is hoped that with larger, randomized trials as well as novel treatment approaches, there may be improved results in patients with this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
